Charity seeks diagnostic partners to deliver new patient treatments
MRC Technology has launched a Call for Diagnostics. It is seeking academic and industry collaborators to develop diagnostic tests in areas of unmet patient needs.
MRC Technology strengthens its collaborative relationships in Scandinavia
MRC Technology (MRCT) and the University of Turku (UTU, Finland) have signed a memorandum of understanding outlining…
Dementia Consortium signs new pharma partner Astex Pharmaceuticals
The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals (Astex) as a new member.
Charity and academic collaboration aims to find drug treatment for lymphoma
MRC Technology and the University of Lausanne are collaborating to find new drug treatments for diffuse large B cell lymphoma, the most common type of non-Hodgkin lymphoma.
EU Consortium receives funding for detection and prevention of diseases associated with ageing
Marie Skłodowska-Curie actions has awarded €2,887,054.24 to an EU consortium, including MRC Technology, to provide training for 11 young researchers in innovative therapeutic strategies.
Dementia Consortium funds project focusing on ALS and FTLD
A project to identify new agents capable of stimulating clearance of a protein that forms aggregates in neurons of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD) has received funding worth £305,000 from the Dementia Consortium.
NICE recommends pembrolizumab made available on the NHS for advanced skin cancer (antibody humanized by MRC Technology)
Pembrolizumab, an immunotherapy treatment for advanced melanoma (skin cancer), was approved by "The National Institute for Health and Care Excellence (NICE)" in final draft guidance.
Georg-August-University Göttingen, Universitätsmedizin and MRC Technology collaborate to develop new therapy for neurodegenerative diseases
Georg-August-University Göttingen (UMG) and MRC Technology (MRCT) have signed a collaboration agreement for the development of a novel therapy for neurodegenerative diseases based on an antibody that targets particular forms of amyloid beta peptides, amyloid beta 4-x. The aim is to develop a new antibody therapy for Alzheimer’s Disease (AD).
Keytruda receives EU marketing approval (antibody humanised by MRC Technology)
Keytruda receives European Commission approval for treatment of advanced melanoma in all EU member states.